Evidencia científica

Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis.

Satoshi Tanida 1, Tsutomu Mizoshita 1, Hirotada Nishie 1, Keiji Ozeki 1, Takahito Katano 1, Eiji Kubota 1, Hiromi Kataoka 1, Takeshi Kamiya 1, Takashi Joh 1 , J Clin Med Res. 2015 Nov;7(11):884-9.

It was concluded that combination therapy with ADA plus intensive GMA is useful for induction of clinical remission in refractory UC patients, and is well tolerated.

https://pubmed.ncbi.nlm.nih.gov/26491502/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596271/pdf/jocmr-07-884.pdf

Adalidumab / Clinical remission / Long-term efficacy / Refractory patients /

ContáctanosPara solicitar información adicional

Contáctanos